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Abstract
Background: Heart type fatty acid binding protein (H-FABP) has been closely associated with acute coronary
syndrome, cardiac abnormalities, stroke, and obstructive sleep disorder in previous studies. The aim of this study
was to evaluate and compare the serum H-FABP levels and carotid artery intima-media thickness (CIMT) between
patients with prediabetes and control subjects.
Research design and methods: We measured serum H-FABP levels in 58 prediabetic patients, 29 with impaired
fasting glucose (IFG) and 29 with impaired glucose tolerance (IGT) and 28 age-, sex- and body mass index-matched
control subjects using a sandwich enzyme-linked immunosorbent assay (ELISA), and in order to measure CIMT, all
participants underwent high-resolution B-mode ultrasonography.
Results: Serum H-FABP levels were significantly elevated in pre-diabetic patients when compared with that of
control subjects (IFG: 32.5 ± 34.2 ng/dL, IGT: 45.4 ± 45.8 ng/dL, control: 16.8 ± 14.9 ng/dL; p = 0.011). The
difference in means of H-FABP levels between patients with IGT or IFG and control subjects was significant (p =
0.010 and p = 0.009, respectively). CIMT was higher in the pre-diabetic groups compared with the control group
(IFG: 0.6 ± 0.1, IGT: 0.6 ± 0.1, control: 0.5 ± 0.1; p < 0.001), and H-FABP level was positively correlated with CIMT
(p < 0.001, rho = 0.626).
Conclusion: Our results indicate that patients with pre-diabetes are at increased risk for cardiovascular disease. In
addition, serum H-FABP levels could represent a useful marker for myocardial performance in patients with IFG
and IGT.
Background
Abnormalities of glucose metabolism are most com-
monly diagnosed using the threshold criteria for impaired
glucose tolerance (IGT) or impaired fasting glucose (IFG)
established by the American Diabetes Association (ADA)
and the World Health Organization (WHO) [1-3]. These
two pre-diabetic states were initially recognized as condi-
tions associated with increased risk of progression to
type 2 diabetes mellitus. In addition to the elevated
glucose levels, pre-diabetes is associated with the classic
cardiovascular risk factors, such as obesity, hypertension,
and dyslipidemia [4-6]. IGT and IFG differ from one
another in many aspects, including the associated cardio-
vascular risk [7]. Whereas ample evidence points to a
strong relationship between IGT and cardiovascular mor-
bidity and mortality, it is still unclear whether there is a
relationship between IFG and cardiovascular disease [8,9].
Heart-type fatty acid binding protein (H-FABP) is abun-
dant in the cytosol of cardiomyocytes, and transports fatty
acids in these cells. It is a powerful regulator of the mito-
chondrial beta-oxidative system in the heart [10]. Molecu-
lar size and intracellular location are important factors
* Correspondence: b_karbek@yahoo.com
1Department of Endocrinology and Metabolism, Dışkapı Yıldırım Beyazıt
Teaching and Research hospital, Ankara, Turkey
Full list of author information is available at the end of the article





© 2011 Karbek et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.determining the kinetic release of cardiac biomarkers.
Small cytoplasmic molecules such as H-FABP (15 kDa)
appear earlier (2-4 h) than larger ones, which are mainly
associated with myofibrils, as cardiac troponins (6-12 h)
[11]. Therefore, H-FABP has been used as a diagnostic
marker for acute coronary syndrome (ACS). Other studies
have demonstrated that serum levels of H-FABP are
increased in patients with hypertrophic and dilated cardio-
myopathy, heart failure, stroke, obstructive sleep apnea,
a n dp u l m o n a r ye m b o l i s m[ 1 2 ] .C a r o t i da r t e r yi n t i m a -
media thickness (CIMT) is an intermediate phenotype for
early atherosclerosis. High CIMT values have been asso-
ciated with cardiovascular disease, coronary atherosclerosis,
and related risk factors in cross-sectional studies [13,14].
Further, since CIMT can be measured relatively simply
and noninvasively, it represents a useful diagnostic tool.
The aim of the present study was to compare serum
H-FABP levels, CIMT, and cardiovascular risk factors of
IFG and IGT patients with those of controls having nor-
mal glucose tolerance (NGT). In addition, to discern
any possible differences between the two pre-diabetic
groups, values for these three parameters in IFG patients
were compared with those in IGT patients.
Materials and methods
The present study was performed at the Endocrinology
Department of Diskapi Yildirim Beyazit Training and
Research Hospital, during the period January 2010-July
2010. Fifty-eight patients with pre-diabetes (29 with
IGT, mean age: 46.9 ± 10.4 years, and 29 with IFG,
mean age: 45.2 ± 10.3 years) along with 28 control sub-
jects with NGT, matched for age, gender, and body
mass index (BMI), were enrolled. The demographic
characteristics of the case and control subjects are
shown in Table 1. The study was approved by the Hos-
pital Ethical Committee and informed consents were
obtained from all participants before the study
procedures.
All participants underwent a standard 75 g oral glu-
cose tolerance test (OGTT) after 12 h fast, with venous
glucose sampling at 0 min and 120 min. Categories of
glucose tolerance were defined according to 2006 WHO
criteria [15]. IFG is defined by an elevated fasting plasma
glucose (FPG) concentration (≥100 and<126 mg/dL). IGT
is defined by an elevated 2-hour plasma glucose concen-
tration (≥140 and<200 mg/dL) after a 75-g glucose load
on the oralglucose tolerance test (OGTT) in the presence
of an FPG concentration <126 mg/dL. Low-density lipo-
protein cholesterol (LDL-C), high-density lipoprotein
cholesterol (HDL-C), total cholesterol (TC), triglycerides,
and fasting serum insulin were estimated. Weight and
height of the subjects were measured, and BMI and
homeostasis model assessment of insulin resistance
(HOMA-IR) were calculated. All participants underwent
high-resolution B-mode ultrasonography. All scans and
image measurements were carried out by the same inves-
tigator, who was blinded to the risk factor status of the
participants. All patients were interviewed using a stan-
dard questionnaire, including demographic characteristics,
concomitant disease, use of medications that could affect
blood glucose and H-FABP levels and smoking history,
and they underwent physical examination. Patients with a
history of ACS, heart failure, pulmonary embolism,
stroke, cardiomyopathy, renal disease and immunological
diseases, or those who were under treatment for these
diseases, were excluded from the study. The control
group composed of volunteers who did not have any his-
tory of cardiological disease, ACS, heart failure, pulmon-
ary embolism, stroke, cardiomyopathy, renal disease,
immunological diseases, and diabetes mellitus.
Heart-type fatty acid binding protein
The human H-FABP ELISA is a ready-to-use solid-
phase enzyme-linked immunosorbent assay based on the
sandwich principle. Samples and standards are incu-
bated together with peroxidase-conjugated second anti-
body in microtiter wells coated with antibodies
recognizing human H-FABP. During incubation human
H-FABP is captured by the solid bound antibody. The
secondary antibodies will bind to the captured human
H-FABP. The peroxidase conjugated antibody will react
with the substrate, tetramethylbenzidine (TMB). The
enzyme reaction is stopped by the addition of oxalic
acid. The absorbance at 450 nm is measured with a
spectrophotometer.
Statistical analyses
The Statistical Package for Social Sciences (SPSS) version
15.0 for Windows was used for the statistical analyses.
Frequency tables for categorical variables and descriptive
statistics (mean, standard deviation, median, minimum,
maximum) for the numerical variables were generated.
Providing the crosstab statistics for the inter-group catego-
rical comparisons, significance levels were examined using
a chi-square test. A t-test was performed to determine dif-
ferences among groups for the normally distributed data.
For non-normally distributed data, the Mann-Whitney U
test was performed for two-group comparisons and the
Kruskal-Wallis test was used for multi-group comparisons.
In order to measure dependence between groups that
were not normally distributed, Spearman’s rho coefficient
was calculated. A p value < 0.05 was considered statisti-
cally significant.
Results
Demographic characteristics and biochemical para-
meters of the patients with IGT, the patients with IFG,
and normal control subjects are shown in Table 1.
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diabetic patients compared with control subjects (IFG:
32.5 ± 34.2 ng/dL, IGT: 45.4 ± 45.8 ng/dL, control: 16.8
± 14.9 ng/dL; p = 0.011, Figure 1). The difference in
means of H-FABP levels between patients with IGT or
IFG and control subjects was significant (p = 0.010 and
p = 0.009, respectively; Table 2). We compared the
serum H-FABP levels of pre-diabetic groups; Although
t h eI G Tg r o u ph a dah i g h e rs e r u mH - F A B Pl e v e l
than the IFG group, the difference was not significant
(p = 0.732).
The mean insulin resistance test (HOMA-IR) values of
the IFG group, IGT group, and control group statisti-
cally differed from each other, the values were 3.4 ± 1.4,
4.1 ± 1.7, and 2.1 ± 1.0, respectively (p < 0.001). How-
ever, HOMA-IR values were not correlated with
H-FABP levels.
CIMT was significantly higher in the pre-diabetic
groups than in the control group (IFG: 0.6 ± 0.1, IGT:
0.6 ± 0.1, control: 0.5 ± 0.1; p < 0.001). However, there
was no significant difference between the CIMT values
of patients in the two pre-diabetic states. H-FABP was
positively correlated with CIMT (Figure 2). In the 86
participants included in the study, a strong relationship
was found between serum H-FABP and CIMT (p <
0.001, rho = 0.626). IFG and IGT groups were examined
separately; There was a significant relationship between
H-FABP and CIMT (IFG group: p < 0,001 rho:0.765
IGT group: p < 0,001 rho:0,613).
No significant correlation was identified between H-
FABP levels and age, gender, BMI, or other biochemical
parameters.
Discussion
The present study confirms that serum levels of
H-FABP are increased in patients with pre-diabetes,
and, for the first time to our knowledge, demonstrates
that elevated circulating serum levels of H-FABP may
Table 1 Demographic characteristics and biochemical data for patients with impaired fasting glucose (IFG), patients
with impaired glucose tolerance (IGT), and control subjects
IFG (n = 29) IGT (n = 29) Control (n = 28) p
Gender, n (%)
Female 23 (79.3) 23 (79.3) 23 (82.1) 0.953
Male 6 (20.7) 6 (20.7) 5 (17.9)
Age (Years), mean ± SD 45.2 ± 10.3 46.9 ± 10.4 44.2 ± 8.1 0.575
BMI (kg/m
2), mean ± SD 27.9 ± 2.4 28.6 ± 3.6 28.6 ± 4.1 0.652
Waist/hip ratio, mean ± SD 0.90 ± 0.07 0.87 ± 0.07 0.85 ± 0.08 0.047
Hypertension, n (%)
Absent 28 (96.6) 27 (93.1) 28 (100.0) 0.770
Present 1 (3.4) 2 (6.9) 0 (0)
Smoking, n (%)
Absent 26 (89.7) 24 (82.8) 25 (89.3) 0.784
Present 3 (10.3) 5 (17.2) 3 (10.7)
Total cholesterol level (mg/dL), mean ± SD 184.9 ± 27.2 187.6 ± 34.9 198.1 ± 23.3 0.110
LDL level (mg/dL), mean ± SD 117.7 ± 40.3 105.9 ± 32.6 118.2 ± 23.7 0.204
HDL level (mg/dL), mean ± SD memean ± SD 47.9 ± 10.2 52.2 ± 27.3 51.3 ± 11.7 0.533
TG level (mg/dL), mean ± SD 120.9 ± 38.9 148.0 ± 68.9 131.6 ± 48.2 0.364
Fasting blood glucose level (mg/dL), mean ± SD 111.1 ± 5.9 105.1 ± 8.5 92.3 ± 5.0 <0.001
Insulin level, mean ± SD 11.9 ± 4.8 13.1 ± 5.4 9.10 ± 4.2 0.008
HOMA-IR level, mean ± SD 3.4 ± 1.4 4.1 ± 1.7 2.1 ± 1.0 <0.001
HOMA-IR: Homeostatic model assessment BMI: Body mass ındex.
Figure 1 Mean serum heart-type fatty acid binding protein
(H-FABP) levels in patients with impaired fasting glucose (IFG)
and impaired glucose tolerance (IGT), and in control subjects.
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with IFG and IGT. These two pre-diabetic states were
initially recognized as conditions associated with
increased risk of progression to type 2 diabetes mellitus.
A number of studies have demonstrated that pre-dia-
betes is a state of subclinical inflammation, procoagula-
tion, and endothelial dysfunction [4-6]. The two pre-
diabetic states differ from one another in many aspects,
including the associated cardiovascular risk. Whereas
there is ample evidence pointing out a strong relationship
between IGT and cardiovascular morbidity and mortality,
the relationship between IFG and cardiovascular disease
is still unclear and controversial [8,9]. An increased
understanding of the cardiovascular risk associated with
the two categories of pre-diabetes would be of great ben-
efit for the development of screening programs and pre-
ventive strategies for subjects with IFG and IGT.
H-FABP is a cytoplasmic protein with a molecular
weight of 15 kDa, which mediates the passage of fatty
acids from the plasma membrane to sites of lipid synth-
esis. It has been reported that H-FABP is a potent indu-
cer of cardiac myocyte hypertrophy, stimulating an
increase in cell surface area, protein synthesis, and c-jun
expression [16]. Furthermore, H-FABP has been
reported to be a new specific serum biomarker for acute
myocardial infarction [17,18]. Viswanathan et al. [19]
have demonstrated that the prognostic value of elevated
H-FABP is additive to that of troponin in low- and
intermediate-risk patients with suspected ACS. H-FABP
could therefore be of value as a marker of myocardial
ischemia, even in the absence of frank necrosis. Orak et
al. [20] found that for patients admitted to emergency
service (ES) with chest pain, H-FABP was more sensitive
and specific than troponin I and creatinine kinase myo-
cardial band (CK-MB) in the early diagnosis of acute
coronary syndrome. Kyung Su Kim et al [21] confirm
that; the initial H-FABP measured by quantitative
POCT has a better diagnostic value than initial myoglo-
bin or initial CK-MB as an adjunct to the initial cardiac
troponins for the early diagnosis of MI. Łukasz Figiel et
al [22] also showed superior sensitivity of h-FABP com-
pared to glycogen phosphorylase BB (GP-BB) and car-
diac troponin T (cTnT) in patients with ACS. H-FABP
has high diagnostic accuracy in early non-ST-segment
elevation ACS.
Previous studies have shown that H-FABP is not only
a marker of acute myocardial infarction, but of other
conditions as well. Boscheri et al. [23] have reported
that H-FABP significantly predicts mortality in patients
with intermediate risk for pulmonary embolism.
H-FABP could therefore also represent a novel prognos-
tic parameter enabling the optimization of management
strategy in the very difficult population of pulmonary
embolism patients who are at intermediate risk. Akbal
et al. [24] reported that patients with metabolic syndrome
(MetS) have increased serum levels of H-FABP, indicat-
ing its promise as a marker for detection of cardiac injury
during the early asymptomatic period in patients with
MetS. Glatz JF et al. reported that experimental diabetes
induces a marked increase of the FABP content of rat
heart and suggests that this protein is involved in the
enhanced fatty acid utilization by the diabetic heart [25].
In our study, serum H-FABP levels were significantly
elevated in pre-diabetic patients compared with control
subjects (IFG: 32.5 ± 34.2 ng/dL, IGT: 45.4 ± 45.8 ng/dL,
control: 16.8 ± 14.9 ng/dL; p = 0.011). The difference in
Table 2 Serum heart-type fatty acid binding protein
(H-FABP) levels in patients with impaired fasting glucose
(IFG), patients with impaired glucose tolerance (IGT),
and control subjects
Study Groups H-FABP
Mean ± SD p
IFG 32.5 ± 34.2 0.011
IGT 45.4 ± 45.8
Control 16.8 ± 14.9
Difference of Means ± SEM p
IFG-IGT -12.9 ± 10.7 0.732
IFG-control 15.8 ± 6.9 0.009
IGT-control 28.7 ± 9.0 0.010
Figure 2 Relationship between carotid intima-media thickness
and heart-type fatty acid binding protein levels in patient and
control groups. IGT: impaired glucose tolerance, IFG: impaired
fasting glucose, Absent: control group (no prediabetic condition
detected).
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IFG and control subjects was significant (p = 0.010 and
p = 0.009, respectively). Our findings also, suggest that
an elevated circulating level of H-FABP is not only a
highly sensitive and specific marker of myocardial
damage, but is also an important prognostic determinant
in patients with pre-diabetes. Also, an elevated circulating
level of H-FABP can reflect early identification of subcli-
nical atherosclerosis in patients with pre-diabetes.
CIMT is an intermediate phenotype for early athero-
sclerosis. As it can be measured relatively simply and
noninvasively, it is well suited for use in large-scale
population studies. Ultrasonic measurements correlate
well with histology [26], and an increased CIMT is asso-
ciated with vascular risk factors and the presence of
more advanced atherosclerosis [27-30], which includes
coronary artery disease [31-33]. CIMT is being increas-
ingly used for cardiac risk stratification and as an endpoint
in intervention studies. An important precondition for the
application of CIMT is that it can predict future risk of
clinical vascular events. A number of longitudinal studies
have examined the relationship between CIMT and future
events, most frequently the incidence of cardiac events
(specifically, myocardial infarction (MI), angina pectoris,
and coronary intervention) and cerebrovascular events
(stroke or transient ischemic attack) [26-33]. More
recently, a clinical study in type-2 diabetics by Djaberi et
al. [34] reported a significant relationship between CIMT
and abnormal cardiac perfusion. Ito and coworkers [35],
Escobedo and colleagues [36], and Poppe and associates
[37] confirm that vascular imaging can be effectively used
to detect subclinical disease in type 2 diabetics and poten-
tially predict cardiovascular risk. Einarson TR and cowor-
kers [38] who published a meta-analysis of data from
15,592 patients that were described in 11 papers, found
significant relationship between postprandial glucose levels
and CIMT, which have both been associated with adverse
cardiovascular outcomes. In our study, CIMT was signifi-
cantly higher in the pre-diabetic groups than in the control
group (IFG: 0.6 ± 0.1, IGT: 0.6 ± 0.1, control: 0.5 ± 0.1;
p < 0.001). However CIMT was similar in both pre-
diabetic states. In contrast to previous studies, the risk
appeared to be the same in the two categories of pre-
diabetes. Finally, we also found a positive correlation
between H-FABP levels and CIMT (p < 0.001, rho = 0.626).
In conclusion, to the best of our knowledge, the present
study is the first case-control study in which significant
alteration in serum H-FABP levels was detected in
patients with pre-diabetes. H-FABP levels were increased
in patients with IFG and IGT, and serum H-FABP levels
were positively correlated with CIMT. There was no dif-
ference between patient and control groups in other
known cardiovascular risk factors, including age, sex,
cholesterol panels, HT, and smoking. However, serum
H-FABP levels in patients were high and there was a
positive correlation with IMT. H-FABP may therefore
represent a marker for early atherosclerosis in pre-
diabetic patients.
Further studies are required to investigate the relation-
ship between H-FABP levels and long-term development
of cardiac injury and atherosclerosis in patients with
pre-diabetes.
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